Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 4Unknown 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 1Neoplasm Metastasis 1Carcinoid Tumor 1

Interventions

Cisplatin 267Oxaliplatin 194Carboplatin 189Capecitabine 183Docetaxel 176apatinib 164Paclitaxel 158Bevacizumab 155Gemcitabine 154Radiotherapy 146camrelizumab 145Fluorouracil 144Cyclophosphamide 123Irinotecan 119Drug Therapy 118sintilimab 107Etoposide 99anlotinib 90S 1 (combination) 88Leucovorin 85pembrolizumab 82Pemetrexed 78Doxorubicin 77toripalimab 76tislelizumab 75Dexamethasone 70Trastuzumab 65Neoadjuvant Therapy 64Rituximab 62Cetuximab 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × lanreotide × Clear all
NCT04427787 2021-09-05

LOLA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
69 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01731925 2017-01-31

SUNLAND

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Unknown
44 enrolled
Endocrine

Carcinoid Tumor, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡